Why Deals Fail: The Reasons May Be Clinical, Economic Or Strategic
Lessons Can Be Learned From Dud Deals
Executive Summary
Acquisitions and licensing are core to pharma and big biotech growth as pipelines thin and assets lose patent protection. Looking back at significantly sized acquisitions over just five years reveals that half of 2014’s acquisitions can already be judged as outright failures or, at best, questionable. But some lessons can be learned from dud deals.